BNTC:NSD-Benitec Biopharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.94

Change

0.00 (0.00)%

Market Cap

USD 0.03B

Volume

0.22M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD79.98B 133.51 104.16
REGN Regeneron Pharmaceuticals, Inc

N/A

USD57.31B 15.31 11.96
BNTX BioNTech SE

N/A

USD51.30B -99,999.99 31.95
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD48.63B 17.91 12.34
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.06B 58.65 41.96
BGNE BeiGene, Ltd

N/A

USD29.61B N/A N/A
SGEN Seagen Inc

N/A

USD28.37B 43.61 39.21
GMAB Genmab A/S

N/A

USD28.05B 26.59 3.73
RPRX Royalty Pharma plc

N/A

USD26.73B 22.60 15.75
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD20.79B N/A N/A

ETFs Containing BNTC

Symbol Name Weight Mer Price(Change) Market Cap
DX2K:F Xtrackers - FTSE 100 Shor.. 0.00 % 0.50 %

N/A

USD0.01B
DX2K:XETRA Xtrackers FTSE 100 Short .. 0.00 % 0.50 %

N/A

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.33% 76% C 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.33% 76% C 77% C+
Trailing 12 Months  
Capital Gain -52.53% 11% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.53% 11% F 4% F
Trailing 5 Years  
Capital Gain 194.05% 79% C+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 194.05% 79% C+ 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 110.19% 91% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 110.19% 90% A- 94% A
Risk Return Profile  
Volatility (Standard Deviation) 263.18% 9% F 5% F
Risk Adjusted Return 41.87% 67% D+ 60% D-
Market Capitalization 0.03B 3% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 51.55 17% F 21% F
Price/Book Ratio 3.16 60% D- 47% F
Price / Cash Flow Ratio -4.27 30% F 65% D
EV/EBITDA 0.12 76% C 96% A
Management Effectiveness  
Return on Equity -110.15% 21% F 9% F
Return on Invested Capital -48.86% 50% F 17% F
Return on Assets -58.45% 8% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.49 91% A- 85% B
Short Percent 6.06% 56% F 33% F
Beta 1.71 31% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector